GGrantIndex
Sort

64,565 grants matching drug discovery

University of Kentucky Markey Cancer Center - Cancer Center Support Grant

$1,500,000
Bernard Mark Evers · University Of Kentucky · P30 · FY2014 · CA

Collaborative Research: Frameworks: Interoperable High-Performance Classical, Machine Learning and Quantum Free Energy Methods in AMBER

$1,500,000
Darrin M York · Rutgers University New Brunswick · · FY2022 · CSE

The CFDE Workbench

$1,500,000
Avi Ma'ayan · Icahn School Of Medicine At Mount Sinai · OT2 · FY2023 · OD

Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate

$1,500,000
Steven E Shoelson · Joslin Diabetes Center · U01 · FY2010 · DK

Development and Commercialization of the Microphysiological Systems Database as a Sustainable Resource

$1,499,999
Mark E Schurdak · University Of Pittsburgh At Pittsburgh · U24 · FY2021 · TR

Northeast Node of the National Drug Abuse Treatment Clinical Trials Network (Doula)

$1,499,999
Lisa A Marsch · Dartmouth College · UG1 · FY2025 · DA

Utah Trial Innovation Center

$1,499,994
Jonathan Michael Dean · University Of Utah · U24 · FY2016 · TR

JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN)

$1,499,981
Norman J Haughey · Johns Hopkins University · P30 · FY2022 · MH

A microfluidic-enabled SmartPlate for precision culture, control and monitoring of living cells. NAICS 5417715 PSC AN12 Contractor DUNS 078744267

$1,499,968
Mary Ludlam · Cairn Biosciences, Inc. · N01 · FY2018 · DA

Novel Protease Inhibitors as SARS Therapeutics

$1,499,929
Michael E. Johnson · University Of Illinois At Chicago · P01 · FY2006 · AI

Development of a novel, preferring potentiator of GABAA receptor for treatment of epilepsy

$1,499,869
Rok Cerne · Respirerx Pharmaceuticals Inc. · R44 · FY2025 · NS

UAB Center for AIDS Research

$1,499,409
Michael S. Saag · University Of Alabama At Birmingham · P30 · FY2018 · AI

Emory-GSK-NIMH Collaborative Mood Disorders Initiative

$1,499,366
Emory University · U19 · FY2005 · MH

Preclinical development of AST-004 for astrocyte-mediated treatment of TBI.

$1,499,342
Theodore E Liston · Astrocyte Pharmaceuticals, Inc. · R44 · FY2019 · NS

Fox COBRE Phase II Admin Core

$1,498,202
Joseph M Fox · University Of Delaware · P20 · FY2023 · GM

CHEMICAL GENETIC APPROACHES TO BASIC CELL BIOLOGY

$1,498,111
Harvard University (Medical School) · P01 · FY2004 · GM

NICHD: R&D: PRECLINICAL SAFETY AND TOXICOLOGY STUDIES FOR REGULATORY REQUIREMENTS: NON-SEVERABLE

$1,497,846
Deborah Bunin · Sri International · N01 · FY2025 · HD

Novel Protease Inhibitors as SARS Therapeutics

$1,497,577
Michael E. Johnson · University Of Illinois At Chicago · P01 · FY2007 · AI

Functional Genomics of Bipolar Disorder

$1,497,299
Francis J McMahon · National Institute Of Mental Health · ZIA · FY2016 · MH

Phase IIa study of VBP15 for Duchenne muscular dystrophy

$1,496,525
Eric P Hoffman · Reveragen Biopharma, Inc. · R44 · FY2017 · NS

Preclinical development of AST-004 for astrocyte-mediated treatment of TBI.

$1,496,476
Theodore E Liston · Astrocyte Pharmaceuticals, Inc. · R44 · FY2018 · NS

Phase IIa study of VBP15 for Duchenne muscular dystrophy

$1,495,253
Eric P Hoffman · Reveragen Biopharma, Inc. · R44 · FY2016 · NS

Medical University of South Carolina - Cancer Center Support Grant

$1,495,000
Anthony J Alberg · Medical University Of South Carolina · P30 · FY2014 · CA

Medical University of South Carolina - Cancer Center Support Grant

$1,495,000
Anthony J Alberg · Medical University Of South Carolina · P30 · FY2015 · CA

Decoding Antibiotic-induced Susceptibility to Clostridium difficile Infection

$1,494,740
Tor C. Savidge · Baylor College Of Medicine · U01 · FY2017 · AI